The aim of this study was to determine if ERCP related morbidity is higher if performed out of workinghours. Contemporaneously collected data patients undergoing ERCP at an Australian hospital were analysed. No difference was found in rates of post‐ERCP pancreatitis (PEP) in patients undergoing out of hours ERCP compared with in hours ERCP (p = 0.759).
Hasib Ahmadzai+4 more
wiley +1 more source
Traumatic Acute Pancreatitis as a Cause of Large Bowel Obstruction [PDF]
Ray Bolam
openalex +1 more source
Atorvastatin-Associated Acute Pancreatitis: A Case Report. [PDF]
Alshammari F, Alharbi A, Alshammari RA.
europepmc +1 more source
Molecular and cellular mechanisms underlying gyrate atrophy: Why is the retina primarily affected?
Abstract Gyrate atrophy of the choroid and retina (GACR; OMIM #258870) is a rare early‐onset autosomal recessive disorder, caused by bi‐allelic pathogenic variants in the gene coding for ornithine aminotransferase (OAT) resulting in hyperornithinaemia.
Mark J. N. Buijs+12 more
wiley +1 more source
Comparison of Harmless Acute Pancreatitis Score (HAPS) and Bedside Index of Severity in Acute Pancreatitis (BISAP) Scoring Systems in Predicting Severity and Outcomes in Acute Pancreatitis: A Prospective Study. [PDF]
Meshram N+8 more
europepmc +1 more source
ABSTRACT Aim To assess the prevalence of endocrine disorders and investigate growth patterns in single large‐scale mitochondrial DNA deletion syndromes (SLSMDs). Methods A retrospective study of all children with SLSMD who attended Sheba Medical Center, Israel, from February 2017 to September 2024.
Ayman Daka+7 more
wiley +1 more source
Experimental Study on the Urinary 17-KS Excretion in Acute Pancreatitis
Ichiro Inoue
openalex +2 more sources
Prostaglandin release in canine acute haemorrhagic pancreatitis. [PDF]
G Glazer, A. B. Bennett
openalex +1 more source
Atypical presentation of painless acute pancreatitis: A case report. [PDF]
Sargon K+5 more
europepmc +1 more source
Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen+3 more
wiley +1 more source